Juan Manuel Ramos-Goñi
5PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 04, 2024
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz
|Jan 20, 2024
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz
|Dec 10, 2023
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication.Jen-Yu Amy Chang, Chien-Ning Hsu, Juan Manuel Ramos-Goñi
|Oct 28, 2023
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz
|Feb 16, 2022
Exploring the Comparability of Face-to-Face Versus Video Conference-Based Composite Time Trade-Off Interviews: Insights from EQ-5D-Y-3L Valuation Studies in Belgium and Spain.Anabel Estévez-Carrillo, Sarah Dewilde, Mark Oppe
Pageof 1
